A Comparison of Bupropion SR and Placebo for Smoking Cessation

• Status: Completed
• Trial end date: 2005-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to examine whether the adjunctive use of bupropion SR in the context of a psychoeducational program modified for people with schizophrenia might improve the likelihood of successful abstinence in this population. If bupropion SR is effective for reducing cigarette smoking, then it will be important to determine if decreased nicotine intake is associated with a worsening of psychotic, anxiety or depressive symptoms. In addition, it would be important to determine the effect that a reduction in nicotine stimulation would have on patient's cognitive functioning, as nicotinic receptors have been shown to regulate attention and memory function, and it is hypothesized that these functions are normalized by acute nicotine administration in people with schizophrenia

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Maryland; University of Maryland, Baltimore
• Collaborators: US Department of Veterans Affairs; VA Office of Research and Development
• Treatments: Bupropion

Criteria

Inclusion Criteria:

• Inclusion Criteria are:

1. DSM-IV diagnosis of Schizophrenia or schizoaffective disorder

2. Age: 18-64

3. Regular half pack a day smokers

4. Score of at least 4 on the Nicotine Dependency Test

Exclusion Criteria:

Exclusion Criteria are:

1. Seizure disorders, other Neurologic illnesses, or a family history of seizures

2. A medical condition that could manifest psychiatrically

3. Currently experiencing a depressive episode

4. Active substance abuse

5. Currently receiving bupropion

6. Pregnant women

7. Children (<18 years of age)

8. Two consecutive sodium levels of 130 mmol/L or less